Raremark raises £3m to enable precision medicine in rare disease
Oltre Venture and, existing major investor, the Cass Entrepreneurship Fund also invested.
The funding will be used to develop Raremark’s patient-engagement and data-analysis technology, helping biopharmaceutical companies to identify, engage and learn from patients, accelerating the development of new treatments.
Raremark’s platform is the foundation for building research networks of rare disease patients and their families. Raremark provides biopharmaceutical companies with access to anonymized and aggregated patient data, helping to reduce the time and cost of clinical development.